Nathan Caffo
Corporate Officer/Principal bei CANDEL THERAPEUTICS, INC.
Aktive Positionen von Nathan Caffo
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CANDEL THERAPEUTICS, INC. | Corporate Officer/Principal | 01.09.2020 | - |
Karriereverlauf von Nathan Caffo
Ehemalige bekannte Positionen von Nathan Caffo
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ALX ONCOLOGY HOLDINGS INC. | Corporate Officer/Principal | 01.09.2018 | 01.09.2020 |
Presage Biosciences, Inc.
Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA. | Vorstandsvorsitzender | 01.04.2009 | 17.07.2018 |
Präsident | 01.04.2009 | 01.08.2018 |
Ausbildung von Nathan Caffo
The Pennsylvania State University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Corporate Officer/Principal | 2 |
Chief Executive Officer | 1 |
President | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ALX ONCOLOGY HOLDINGS INC. | Health Technology |
CANDEL THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Presage Biosciences, Inc.
Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA. | Health Technology |
- Börse
- Insiders
- Nathan Caffo
- Erfahrung